ObsEva is developing a novel generation of drugs addressing serious conditions compromising pregnancy
from conception to birth
Our management & collaborators combine successful experiences and track records in managing drug development and business development in large pharma & biotech companies.
The Board of Directors is composed of founders, international investors specialised in biotech and independent executives from top pharma companies.
ObsEva also benefits from the expertise of an independent & international advisory team (Scientific Advisory Board) composed of high level, academic specialists in OB-GYN and reproductive medicine.
ObsEva has worldwide exclusive licenses for an orally active, Oxytocin receptor Antagonist (OBE001) and an orally active, Prostaglandin F2α receptor Antagonist (OBE002).
How to contact ObsEva ?» contact us